Cytospire Raised £61M to Aim a Strange Kind of Immune Cell at Cancer

Most cancer immunotherapy is built around one famous kind of immune cell, the alpha-beta T cell, which the entire CAR-T revolution was built on. Cytospire Therapeutics, based in Altrincham near Manchester, is betting on a stranger, less-celebrated cousin, the gamma delta T cell, and just raised £61 million to find out if that bet pays off in patients.

The Series A was led with backing from the British Business Bank, Modi Ventures, Abingworth, 4BIO Capital and Sound Bioventures, a syndicate that mixes patient government-linked capital with specialist life-sciences funds, which is the right shape for something this far from revenue. The company is developing “first-in-class pan-gamma delta T cell engager antibodies,” which is a mouthful that translates, roughly, to: molecules designed to recruit this overlooked immune cell to attack tumours.

A £61 million Series A in biotech doesn’t buy a product. It buys the right to spend years finding out whether the science survives a human body. That’s the deal, and everyone at the table knows it.

The money does one thing: it pushes Cytospire’s multispecific cancer-immunotherapy pipeline into clinical trials. That’s the whole story, and it’s the only story that matters in early oncology, everything before the clinic is hypothesis. The science is genuinely interesting because gamma delta T cells have properties alpha-beta cells don’t, but “interesting in principle” and “works in patients” are separated by a decade and a startling failure rate.

The reason it belongs in a record of European momentum is less about Cytospire specifically and more about the category. Healthcare and biotech were Europe’s second-largest funding sector last year, and the UK keeps producing serious, science-heavy oncology companies that can raise eight-figure rounds without decamping to Boston. Cytospire may work or it may join the long list of elegant immunotherapies that didn’t. Either way, a Manchester-area lab just got £61 million to take a real swing, and that’s the part the pessimists keep leaving out.